Prednisolone eye drop in chronic central serous chorioretinopathy: a randomised clinical trial

Phase 1

• Conditions: chronic central serous chorioretinopathy; Therapeutic area: Diseases [C] - Eye Diseases [C11]

• Registration Number: EUCTR2022-000338-41-NL
• Lead Sponsor: Stichting Radboud universitair medisch centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-28
• Last Update Posted: 16 May 2022

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

- diagnosis of severe chronic central serous chorioretinopathy
- 18 years or older and doesn’t meet any exclusion criteria
- is willing to sign the consent form
- is able to self-administer eye drops.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- when there is evidence of another retinal diagnoses, such as a history of exudative age-related macular degeneration, suspicion of secondary choroidal neovascularization, polypoidal choroidal vasculopathy, multifocal choroiditis, retinal vascular occlusions, pseudoxanthoma elasticum, amblyopia, and severe myopia (more than -6 dioptres)
- woman that are pregnant or breast feeding

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified